Rilzabrutinib not checked
Sanofi · SAR444671 · PRN1008
FollowEvery change as it happens, and a Monday email
Trials
11 active
23 in total · 10 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- Tested for
- Immune Thrombocytopenia (2 trials), Sickle Cell Disease, Autoimmune Haemolytic Anaemia, Immunoglobulin G4 Related Disease, Immunodeficiency Common Variable, Warm Autoimmune Hemolytic Anemia (wAIHA), Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion and 2 more
- Main trialPhase 3
- “This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib. The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed the LTE of the LUNA 3 study in Japan, demonstrating clinically meaningful benefit as judged by the Investigator.”In the company’s words, NCT07216079 on ClinicalTrials.gov
- Other names
- SAR444671 · PRN1008 · PRN1008/SAR444671 · BTK inhibitor
Other drugs for Immune Thrombocytopenia
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- TQB3473Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Efgartigimodargenx · Phase 3
- QL0911Qilu Pharmaceutical · Phase 3
- MezagitamabTakeda · Phase 3
Coming up9
- 25 NovPhase 3 trial completes · ClinicalTrials.gov
- 23 DecPhase 2 trial completes · ClinicalTrials.gov
- 11 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 21 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 23 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 5 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 28 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 10 May 2035Phase 2/3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovCompletion date moved: 2026-11-30 to 2026-11-25 · ClinicalTrials.gov NCT07216079
Trials23
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 25 Nov 2026 | Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | |
| Phase 3Recruiting | 23 Jul 2027 | The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease | |
| Phase 3Recruiting | 5 Nov 2027 | Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment | |
| Phase 3Recruiting | 31 May 2028 | A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia | |
| Phase 3Recruiting | 28 Jun 2028 | A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease | |
| Phase 2/3Not yet recruiting | 10 May 2035 | Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and Tolerability | |
| Phase 2Active, not recruiting | 23 May 2024 | Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) | |
| Phase 2Recruiting | 23 Dec 2026 | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | |
| Phase 2Recruiting | 11 Feb 2027 | A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | |
| Phase 1Active, not recruiting | 3 Nov 2026 | An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition | |
| Phase 1Recruiting | 21 Apr 2027 | Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function | |
| Phase 3Terminated | 30 Jul 2021 | A Study of PRN1008 in Patients With Pemphigus | |
| Phase 3Completed | 15 Jan 2025 | Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) | |
| Phase 2Completed | 18 Dec 2019 | A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris | |
| Phase 2Completed | 31 Jan 2023 | A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) | |
| Phase 2Completed | 23 Jun 2023 | Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis | |
| Phase 2Completed | 19 Jul 2023 | Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine | |
| Phase 2Completed | 6 Feb 2024 | Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma | |
| Phase 2Completed | 15 Oct 2024 | Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants | |
| Phase 1Completed | 23 Mar 2021 | A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008) | |
| Phase 1Completed | 12 Apr 2021 | Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects | |
| Phase 1Completed | 21 May 2021 | Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants | |
| Phase 1Completed | 23 Apr 2024 | A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026